
Opinion|Videos|May 7, 2025
Exploring the Impact of Bronchiectasis Exacerbations
Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.
Advertisement
Episodes in this series

Clinical Brief: Causes and Management of Bronchiectasis Exacerbations
Main Discussion Topics
- Exacerbations are commonly triggered by bacterial infections, viral etiologies, and environmental factors.
- Impaired mucosal clearance significantly contributes to recurrent exacerbations.
- Management approaches include multiple modalities targeting different aspects of the disease.
Key Points for Physicians
- Monitor for increased cough, phlegm, fatigue, and hemoptysis as signs of exacerbation.
- Treatment options include:
- Oral, intravenous, or inhaled antibiotics based on severity
- Airway clearance devices (Vest, oscillating positive expiratory pressure devices like AerobikA/Acapella)
- Breathing techniques and mechanical assistance
- Anti-inflammatory approaches (DPP1 inhibitors, inhaled corticosteroids for eosinophilic phenotype)
- Consider surgical intervention for refractory cases
Notable Insights
Comprehensive management must address multiple dimensions, including infection control, inflammation reduction, mucus clearance enhancement, and hydration.
Clinical Significance
Effective bronchiectasis exacerbation management requires targeted multimodal therapies addressing both immediate symptoms and underlying mechanisms to prevent recurrence.
Advertisement
Related to this article

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5

